読み込み中
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
前日終値
$1.07
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
日中レンジ
現在 $1.07
52週レンジ
現在 $1.07
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
25
割高
センチメント
64
強気
リスク
69
高リスク
モメンタム
29
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
日中レンジ
現在 $1.07
52週レンジ
現在 $1.07
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 9.1万 USD | 10.6万 USD | — | — |
| 粗利益 | — | −9.1万 USD | −10.6万 USD | — | — |
| 研究開発 | 628.3万 USD | 663万 USD | 572.4万 USD | 773.6万 USD | 615.3万 USD |
| 販売・一般管理 | 824.7万 USD | 499.5万 USD | 413.1万 USD | 558.1万 USD | 541万 USD |
| 営業費用 | 1474.3万 USD | 1153.4万 USD | 974.9万 USD | 1328.1万 USD | 1135.7万 USD |
| 受取利息 | 128.5万 USD | 18.2万 USD | 22.8万 USD | 5.4万 USD | 4.4万 USD |
| 減価償却費と償却費 | 4.7万 USD | 9.1万 USD | 10.6万 USD | 10.2万 USD | 7.6万 USD |
| 営業利益 | −1474.3万 USD | −1162.5万 USD | −985.5万 USD | −1328.1万 USD | −1135.7万 USD |
| 純利益 | −1314.2万 USD | −1144.3万 USD | −1074万 USD | −1316.8万 USD | −1131.3万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは4件と限定的です
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2018年9月5日 | 1:15 | — | — |
株式分割 | 2016年11月29日 | 1:9 | — | — |
株式分割 | 2016年5月9日 | 1:12 | — | — |
株式分割 | 2011年7月6日 | 1:10 | — | — |
発効済み 2018年9月5日
1:15
発効済み 2016年11月29日
1:9
発効済み 2016年5月9日
1:12
発効済み 2011年7月6日
1:10
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Invesco NASDAQ Future Gen 200 ETFQQQSAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
